This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AANMA Supports Prescription-Only Pseudoephedrine Legislation

MCLEAN, Va., Feb. 13, 2013 /PRNewswire-USNewswire/ -- Meth addiction is a worldwide epidemic of unimaginable proportions, with an estimated 15,000 deaths in the United States alone last year. States with prescription-only pseudoephedrine laws show a decrease in meth labs, according to a Government Accountability Office (GAO) report released today.

Allergy & Asthma Network Mothers of Asthmatics (AANMA) supports legislation to return pseudoephedrine (PSE) medications to the prescription-only status they held prior to 1976. PSE, a sinus decongestant, is not included as an appropriate asthma medication in the National Institutes of Health Guidelines for the Diagnosis and Management of Asthma.

"Pseudoephedrine hydrochloride, which is the key ingredient for the manufacturing of methamphetamines, does not serve a significant role in the care of patients who suffer from allergic or non-allergic rhinitis," says Stuart W. Stoloff, MD, FAAAAI, FAAFP, clinical professor of family and community medicine, University of Nevada School of Medicine. "Other medications including saline offer a safer option when treating nasal congestion whether it be associated with the common cold, allergic, or non-allergic rhinitis. Given the enhanced safety profile of these other medications, there is no role for pseudoephedrine hydrochloride to be readily available to patients as a 'behind the counter' medication that does not require a prescription written by a qualified medical practitioner."

In 28 years, AANMA has never heard from asthma and allergy patients who rely on non-prescription oral decongestants for their condition.

The most recent data from law enforcement indicates that diversion of legally produced PSE to methamphetamine production in small, toxic "one-pot" labs continues to rise everywhere except in the two states ( Oregon in 2006, Mississippi in 2010) where a prescription is now required. Thus, it seems almost ludicrous not to take advantage of an easy solution to the meth lab problem that requires only the stroke of a pen for implementation.

Preventing the diversion of PSE to the manufacture of methamphetamine is far more urgent and vital to the public interest than continued availability of any particular remedy for the common cold.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs